Both Natus Medical Incorporated (NASDAQ:BABY) and Lantheus Holdings Inc. (NASDAQ:LNTH) are Medical Appliances & Equipment companies, competing one another. We will compare their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natus Medical Incorporated	530.89M	1.70	22.93M	-0.61	0.00
Lantheus Holdings Inc.	343.37M	2.68	40.52M	1.03	22.96

In table 1 we can see Natus Medical Incorporated and Lantheus Holdings Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
Natus Medical Incorporated	-4.32%	-5.2%	-3.1%
Lantheus Holdings Inc.	11.80%	79.2%	9.8%

Volatility and Risk

A beta of 0.52 shows that Natus Medical Incorporated is 48.00% less volatile than S&P 500. Lantheus Holdings Inc.’s 57.00% more volatile than S&P 500 volatility due to the company’s 1.57 beta.

Liquidity

Natus Medical Incorporated’s Current Ratio is 2.6 while its Quick Ratio is 1.9. On the competitive side is, Lantheus Holdings Inc. which has a 3.7 Current Ratio and a 3.1 Quick Ratio. Lantheus Holdings Inc. is better positioned to pay off short and long-term obligations compared to Natus Medical Incorporated.

Analyst Recommendations

Natus Medical Incorporated and Lantheus Holdings Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Natus Medical Incorporated	0	0	0	0.00
Lantheus Holdings Inc.	0	1	0	2.00

Lantheus Holdings Inc. on the other hand boasts of a $22 average target price and a -7.99% potential downside.

Insider & Institutional Ownership

Institutional investors owned 98.2% of Natus Medical Incorporated shares and 96.5% of Lantheus Holdings Inc. shares. About 1.6% of Natus Medical Incorporated’s share are owned by insiders. On the other hand, insiders owned about 2.3% of Lantheus Holdings Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Natus Medical Incorporated	1.68%	-15.53%	-19.42%	-22.66%	-8.36%	-16.25%
Lantheus Holdings Inc.	-1.42%	40.07%	33.48%	56.03%	58.65%	50.54%

For the past year Natus Medical Incorporated has -16.25% weaker performance while Lantheus Holdings Inc. has 50.54% stronger performance.

Summary

On 11 of the 12 factors Lantheus Holdings Inc. beats Natus Medical Incorporated.

Natus Medical Incorporated provides newborn care and neurology healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The companyÂ’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. It offers diagnostic electroencephalography (EEG), ambulatory EEG, and long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology systems. The company also provides hearing screening products to screen the hearing; brain injury products to diagnose the severity of brain injury; and thermoregulation products to control the incubators and warmers. In addition, it offers jaundice management products to treat jaundice; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; NicView streaming video for families with babies in the neonatal intensive care unit; and nursery essential products used in the everyday operation of a newborn intensive care unit. Further, the company provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. The company was founded in 1987 and is headquartered in Pleasanton, California.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow. The company also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging (MPI) procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company offers Additionally, it is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; 18F LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function with positron emission tomography; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.